Earlier this month, the Drug Enforcement Administration issued two Notices of Intent to temporarily ban substances derived from kratom, an herbal stimulant used by many Americans for relief from anxiety, pain, and opioid withdrawal. The move was commended by the FDA and the Department of Health and Human Services, with officials framing it as a victory for public health.
The action would classify the compound 7-hydroxymitragynine (7-OH) and three other kratom-related substances in the same category as heroin and LSD, under Schedule I of the Controlled Substances Act (CSA), meaning they have no accepted medical use and a high potential for abuse. Natural leaf kratom, which dodged a scheduling attempt from the DEA in 2016, would not be affected by the ruling.
The DEA announcement has been brewing ever since the FDA recommended classifying 7-OH as Schedule I in July 2025,…




